Hyattsville, Maryland Clinical Trials

A listing of Hyattsville, Maryland clinical trials actively recruiting patient volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 106 clinical trials
Ustekinumab (Anti-IL-12/23p40 Monoclonal Antibody) in Patients With Leukocyte Adhesion Deficiency Type 1 (LAD1) Who Have Inflammatory Pathology

Background The disease leukocyte adhesion deficiency type 1 (LAD1) affects white blood cells. Those are immune system cells. In people with LAD1, white blood cells do not properly communicate with the rest of the body. This causes uncontrolled inflammation, particularly in the gums. People with LAD1 can get frequent infections …

National Institutes of Health Clinical Center
 (9.7 away) Contact site
  • 21 views
  • 14 Oct, 2020
  • 1 location
Oral Decitabine and Tetrahydrouridine as Epigenetic Priming for Pembrolizumab-Mediated Immune Checkpoint Blockade in Patients With Inoperable or Unresectable Locally Advanced or Metastatic Non-Small Cell Lung Cancers and Esophageal Carcinomas

Background Non-small cell lung cancer (NSCLC) is the most common type of lung cancer. Lung cancer is the leading cause of cancer-related death in the United States. Most people with lung cancer are already in the advanced stages of the disease by the time they see a doctor. Researchers want …

measurable disease
platinum-based chemotherapy
corticosteroids
immunosuppressive
cancer chemotherapy
National Institutes of Health Clinical Center
 (9.7 away) Contact site
  • 21 views
  • 27 Nov, 2020
  • 1 location
T-DM1 Alone Versus T-DM1 and Metronomic Temozolomide in Secondary Prevention of HER2-Positive Breast Cancer Brain Metastases Following Stereotactic Radiosurgery

Background Sometimes breast cancer spreads (metastasizes) to the brain. Researchers want to study new treatments for brain metastases. The drug Temozolomide is approved to treat brain tumors. Researchers want to see if combining it with the drug T-DMI prevents the formation of new metastases in the brain. Objective To study …

erbb2
stereotactic radiosurgery
her2/neu-positive breast cancer
mammogram
HER2
National Institutes of Health Clinical Center
 (9.7 away) Contact site
  • 38 views
  • 23 Nov, 2020
  • 1 location
PROSTVAC in Combination With Nivolumab in Men With Prostate Cancer

Background The immune system is the cells and organs in the body that recognize and fight infection and cancer. The PROSTVAC vaccine might teach the immune system to find and kill certain prostate cancer cells. Nivolumab is a drug that allows the immune system to fight tumors. Itmight help PROSTVAC …

bilateral orchidectomy
prostatectomy
bone scan
testosterone level
biopsy of prostate
National Institutes of Health Clinical Center
 (9.7 away) Contact site
  • 38 views
  • 02 Dec, 2020
  • 1 location
Study of RS1 Ocular Gene Transfer for X-linked Retinoschisis

Background X-linked juvenile retinoschisis (XLRS) is caused by changes in the RS1 gene. These changes cause abnormal function of the eye protein retinoschisin. Without normal retinoschisin, the layers of the retina split and vision is lost. Researchers want to try to introduce a healthy RS1 gene into eye cells, to …

National Institutes of Health Clinical Center, 9000 Rockville Pike
 (9.7 away) Contact site
  • 53 views
  • 03 Aug, 2020
  • 1 location
Deep Brain Stimulation Surgery for Focal Hand Dystonia

Researchers want to test a procedure called deep brain simulation (DBS) to treat focal hand dystonia (FHD). A device called a neurostimulator is placed in the chest. It is attached to wires placed in brain areas that affect movement. Stimulating these areas can help block nerve signals that cause abnormal …

brain stimulation
focal dystonia
dyskinesia
botulinum toxin
National Institutes of Health Clinical Center
 (9.7 away) Contact site
  • 19 views
  • 05 Jul, 2020
  • 1 location
Campath/Fludarabine/Melphalan Transplant Conditioning for Non-Malignant Diseases

The hypothesis for this study is that a preparative regimen that maximizes host immunosuppression without myeloablation will be well tolerated and sufficient for engraftment of donor hematopoietic cells. It is also to determine major toxicities from these conditioning regimens, within the first 100 days after transplantation.

graft versus host disease
thalassemia
hemoglobin s
fludarabine
transplant conditioning
George Washington University School of Medicine
 (5.4 away) Contact site
  • 142 views
  • 27 May, 2020
  • +19 other locations
Safety of a Single Administration of AAV2hAQP1 an Adeno-Associated Viral Vector Encoding Human Aquaporin-1 to One Parotid Salivary Gland in People With Irradiation-Induced Parotid Salivary Hypofunction

Background Radiation can cause the parotid salivary glands to make less saliva (dry mouth). This can cause problems like infections and tooth decay. Researchers hope a new drug can help people with dry mouth caused by radiation. Objectives To examine the safety of AAV2hAQP1 gene therapy. To see if the …

National Institutes of Health Clinical Center, 9000 Rockville Pike
 (9.7 away) Contact site
  • 0 views
  • 11 Nov, 2020
  • 1 location
Phase 1/2 Trial of TC-210 T Cells in Patients With Advanced Mesothelin-Expressing Cancer

TC-210 T cells are a novel cell therapy that consists of autologous genetically engineered T cells expressing a single-domain antibody that recognizes human Mesothelin, fused to the CD3-epsilon subunit which, upon expression, is incorporated into the endogenous T cell receptor (TCR) complex. This Phase 1/2 study aims to establish the …

leukapheresis
ejection fraction
peritoneal mesothelioma
cancer
adenocarcinoma
National Cancer Institute
 (9.6 away) Contact site
  • 38 views
  • 05 Nov, 2020
  • +6 other locations
A Phase 1/2 Study of Intravenous Gene Transfer With an AAV9 Vector Expressing Human <=-Galactosidase in Type I and Type II GM1 Gangliosidosis

Background GM1 gangliosidosis is a disorder that destroys nerve cells. It is fatal. There is no treatment. People with GM1 are deficient in a certain enzyme. A gene therapy may help the body make this enzyme. This could improve GM1 symptoms. Objective To test if a gene therapy helps type …

National Institutes of Health Clinical Center
 (9.7 away) Contact site
  • 1 views
  • 08 Oct, 2020
  • 1 location